| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Recruiting | N/A | 1200 | Europe | UDCA, ursodeoxycholic acid, Ocaliva, obeticholic acid | University of Leipzig, RWTH Aachen University, Zentrum für Klinische Studien Leipzig, Intercept Pharma Europe Limited (IPEL), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University Hospital Erlangen, Medical care center for Gastroenterology, Berlin, Institute for Interdisciplinary Medicine, Hamburg, Leberhilfe Projekt gUG, Cologne, Hannover Medical School | PBC, Primary Biliary Cholangitis | 03/24 | 03/24 | | |
